MTOR and esophageal adenocarcinoma: For instance, PI3K/MTOR inhibition can delay therapeutic resistance against SMO inhibitors in mouse models of cancer, including BKM120 cotreatment in HH-driven medulloblastoma (36) or cotreatment with the MTOR inhibitor RAD-001 in esophageal adenocarcinoma (37).